Browse OSBPL5

Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass membrane protein Note=Localizes to the cortical endoplasmic reticulum at the endoplasmic reticulum-plasma membrane contact sites.
Domain PF01237 Oxysterol-binding protein
PF00169 PH domain
Function

Lipid transporter involved in lipid countertransport between the endoplasmic reticulum and the plasma membrane: specifically exchanges phosphatidylserine with phosphatidylinositol 4-phosphate (PI4P), delivering phosphatidylserine to the plasma membrane in exchange for PI4P, which is degraded by the SAC1/SACM1L phosphatase in the endoplasmic reticulum. Binds phosphatidylserine and PI4P in a mutually exclusive manner (PubMed:23934110, PubMed:26206935). May cooperate with NPC1 to mediate the exit of cholesterol from endosomes/lysosomes (PubMed:21220512). Binds 25-hydroxycholesterol and cholesterol (PubMed:17428193).

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006869 lipid transport
GO:0006892 post-Golgi vesicle-mediated transport
GO:0006893 Golgi to plasma membrane transport
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0010876 lipid localization
GO:0015748 organophosphate ester transport
GO:0015850 organic hydroxy compound transport
GO:0015914 phospholipid transport
GO:0015918 sterol transport
GO:0016125 sterol metabolic process
GO:0030301 cholesterol transport
GO:0048193 Golgi vesicle transport
GO:0098876 vesicle-mediated transport to the plasma membrane
GO:1901615 organic hydroxy compound metabolic process
GO:1902652 secondary alcohol metabolic process
Molecular Function GO:0001786 phosphatidylserine binding
GO:0005319 lipid transporter activity
GO:0005496 steroid binding
GO:0005543 phospholipid binding
GO:0005548 phospholipid transporter activity
GO:0008142 oxysterol binding
GO:0015485 cholesterol binding
GO:0032934 sterol binding
GO:0035091 phosphatidylinositol binding
GO:0043178 alcohol binding
GO:0070273 phosphatidylinositol-4-phosphate binding
GO:0072341 modified amino acid binding
GO:1901981 phosphatidylinositol phosphate binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1482801: Acyl chain remodelling of PS
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483257: Phospholipid metabolism
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OSBPL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OSBPL5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OSBPL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8330.0325
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1070.46
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6280.553
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0780.845
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0990.964
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3010.912
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1860.614
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1660.875
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1440.908
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7490.526
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8390.238
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1660.102
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OSBPL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47028.6-28.60.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OSBPL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OSBPL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OSBPL5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OSBPL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OSBPL5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OSBPL5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOSBPL5
Nameoxysterol binding protein-like 5
Aliases KIAA1534; ORP5; OBPH1; ORP-5; OSBP-related protein 5; oxysterol-binding protein homolog 1; oxysterol-binding ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OSBPL5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.